October 2012 - Volume 32 - Issue 5
pp: 583-740


A Randomized, Double-Blind, Placebo-Controlled Trial of Fluvoxamine in Patients With Schizophrenia: A Preliminary Study

Niitsu, Tomihisa; Fujisaki, Mihisa; Shiina, Akihiro; More

Journal of Clinical Psychopharmacology. 32(5):593-601, October 2012.

Multicenter Study on the Clinical Effectiveness, Pharmacokinetics, and Pharmacogenetics of Mirtazapine in Depression

Sirot, Eveline Jaquenoud; Harenberg, Sabine; Vandel, Pierre; More

Journal of Clinical Psychopharmacology. 32(5):622-629, October 2012.

Does Atomoxetine Improve Executive Function, Inhibitory Control, and Hyperactivity?: Results From a Placebo-Controlled Trial Using Quantitative Measurement Technology

Wehmeier, Peter M.; Schacht, Alexander; Ulberstad, Fredrik; More

Journal of Clinical Psychopharmacology. 32(5):653-660, October 2012.

Pharmacokinetic-Pharmacodynamic Modeling of Mood and Withdrawal Symptoms in Relation to Plasma Concentrations of Methadone in Patients Undergoing Methadone Maintenance Treatment

Shiran, Mohammad-Reza; Lennard, Martin S.; Iqbal, Mohammad-Zafar; More

Journal of Clinical Psychopharmacology. 32(5):666-671, October 2012.


Impact of Switching or Initiating Antipsychotic Treatment on Body Weight During a 6-Month Follow-Up in a Cohort of Patients With Schizophrenia

Schuster, Jean-Pierre; Raucher-Chéné, Delphine; Lemogne, Cédric; More

Journal of Clinical Psychopharmacology. 32(5):672-677, October 2012.

Akathisia and Suicidal Ideation in First-Episode Schizophrenia

Seemüller, Florian; Schennach, Rebecca; Mayr, Andreas; More

Journal of Clinical Psychopharmacology. 32(5):694-698, October 2012.


1 2 3 4 5